EQT AB to Acquire Century Therapeutics for $1.5B

Ticker: IPSC · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1850119

Sentiment: bullish

Topics: acquisition, merger, biotech

TL;DR

EQT's buying Century Therapeutics for $1.5B cash, deal expected Q3 2024.

AI Summary

Century Therapeutics, Inc. announced on June 3, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of EQT AB. The transaction is valued at approximately $1.5 billion, with EQT AB subsidiary agreeing to acquire all outstanding shares of Century Therapeutics for $25.00 per share in cash. The acquisition is expected to close in the third quarter of 2024.

Why It Matters

This acquisition by EQT AB signifies a major consolidation in the cell therapy space, potentially impacting the development and accessibility of Century Therapeutics' pipeline drugs.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the transaction from closing.

Key Numbers

Key Players & Entities

FAQ

What is the total value of the acquisition agreement between Century Therapeutics and EQT AB?

The total value of the acquisition agreement is approximately $1.5 billion.

What is the price per share being offered to Century Therapeutics shareholders?

EQT AB's subsidiary is offering $25.00 per share in cash for all outstanding shares of Century Therapeutics.

When is the acquisition expected to be completed?

The acquisition is expected to close in the third quarter of 2024.

Who is acquiring Century Therapeutics?

A subsidiary of EQT AB is acquiring Century Therapeutics.

What is the filing date of this 8-K report?

The filing date of this 8-K report is June 3, 2024.

Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-03 07:13:44

Key Financial Figures

Filing Documents

01

Item 8.01 Other Events On June 3, 2024, Century Therapeutics, Inc. (the "Company") issued a press release announcing a poster presentation highlighting interim results from the ongoing Phase 1 ELiPSE-1 study evaluating CNTY-101 in relapsed or refractory non-Hodgkin lymphoma at the American Society of Clinical Oncology Annual Meeting being held May 31, 2024 through June 4, 2024 in Chicago, Illinois. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On June 3, 2024, the Company updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Century Therapeutics, Inc., dated June 3, 2024 99.2 Investor Presentation of Century Therapeutics, Inc., dated June 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: June 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing